【摘要】 目的比较肝动脉栓塞化疗(TACE)和索拉非尼在晚期肝细胞癌治疗中的疗效。方法回顾性分析确诊为晚期肝细胞癌(按巴塞罗那标准ECOG评分1-2,Child A/B级,和/或有大血管侵犯或肝外转移)的89例患者的临床资料。其中30例既往接受了TACE治疗,59例患者接受了索拉非尼治疗。观察比较TACE治疗与索拉非尼治疗肿瘤出现恶化的时间和总生存时间。结果接受TACE治疗的患者随访时长的中位数为7.3个月(95%CI:4.0~10.6),病人接受TACE治疗的中位数为(3±2)次;接受索拉非尼治疗时长的中位数为4.3个月(95%CI:2.9~5.8),肿瘤出现恶化时间的中位数在TACE组与索拉非尼组间差异无显著性(P=0.128)。总生存时间的中位数在索拉非尼组中为7.38个月(95%CI:5.2~9.56),TACE组中为8.59个月(95%CI:5.5~11.58,P=0.0164),提示TACE组优于索拉非尼组。结论在晚期肝癌患者(BCLC:C期)中,TACE呈现出了积极的疗效,且略优于索拉非尼。更多还原

【Abstract】 Objective To compare the therapeutic effects of transarterial chemoembolization(TACE)and sorafenib in patients with advanced hepatocellular carcinoma(HCC).Methods The retrospective analysis of the data was analyzed.Patients with advanced HCC according to the Barcelona Clinic Liver Cancer(BCLC)staging classification(ChildPugh class A or B,Eastern Cooperative Oncology Group performance status of 1-2,and/or macrovascular invasion or extrahepatic metastasis)were included in the study(n=89).Thirty patients underwent conventional TACE;59patients were treated with sorafenib.Results The median duration of TACE treatment was 7.3months(95% confidence interval:4.0,10.6months).The median number of TACE per patient was 3±2.The median duration of sorafenib treatment was 4.3months(95% confidence interval:2.9,5.8months).The median time to cancer progression was no significant difference between the two treatment groups(P=0.128).The median overall survival was 8.59 months(95% confidence interval:5.5,11.58 months)for patients treated with TACE and 7.38 months(95% confidence interval:5.2,9.56months)for those treated with sorafenib(P=0.0164).Conclusion TACE achieved a promising therapeutic effect in the patients with advanced HCC(BCLC stage C).更多还原